200 mg-m2 melphalan the gold standard for multiple myeloma
Palumbo and co-authors report on the results of a randomised trial comparing two doses of melphalan in patients with symptomatic multiple myeloma. Overall complete response rates, median progression-free survival and projected five-year overall survival were [more]